DMAC
DiaMedica Therapeutics Inc.
$7.13
-0.51 (-6.68%)
At close · Jul 16
Market Cap
$384.19M
Shares
53,883,345
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$7.13
Open$7.56
Day$7.00–7.56
52W$3.65–10.42
Avg vol 30d228K
Short int5.2M · 9.7% float · 17.7d
Short vol45%
Last earningsMay 6, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 6
Up next
Next earnings call
Aug 6, 2026
Est · unconfirmed
· in 3 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 16.7 · calm
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−1%
below
Price vs 50-day avg
+12%
above
RSI (14)
53
neutral
MACD trend
Negative
52-week position
51%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+25%
trailing
6-month return
−14%
trailing
YTD return
−10%
this year
Relative strength
−23%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $6 › 200d $7 — 200d above 50d
Institutional flow
Distributing
3 of 97 funds reported for Jun 30 · net -164 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
9.66% of float · ▲ +7.1% MoM · 17.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
97 holders — near 3-yr high, broad support
Squeeze score
84
high risk · 0–100
Fundamentals
Free cash flow
$-29.1M
Balance sheet
$15.6M
net cash
Quant / Vol
risk profile
Volatility
66%
annualized · 1-yr
Max drawdown
−43%
past year
ATR
6.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−1%
Neutral
Price vs 50-day avg
+12%
Bullish
RSI (14)
53
Neutral
MACD trend
Negative
Bearish
52-week position
51%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $6 › 200d $7 — 200d above 50d
Institutional flow
Distributing
3 of 97 funds reported for Jun 30 · net -164 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
9.66% of float · ▲ +7.1% MoM · 17.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
97 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $4
Now $7 · 51%
52-wk high $10
vs 200-day avg -1%
vs 50-day avg +12%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DMAC
this stock
DiaMedica Therapeutics Inc.
|
$384.19M | -10.4% | — | — | 9.7% |
|
ONC
BeOne Medicines Ltd.
|
$458.76B | +4.5% | +22179.2% | 933.6 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.36B | +7.2% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$71.18B | -11.9% | +20.8% | 16.6 | 3.3% |
|
ARGX
Argenx SE
|
$53.68B | +2.0% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DMAC | -7.5% | +25.3% | -14.4% | +1.3% | -10.4% |
| SPY | -0.1% | +0.1% | +9.0% | +0.5% | +10.1% |
| vs SPY | -7.4% | +25.3% | -23.4% | +0.8% | -20.5% |